Amneal Pharmaceuticals annual debt-to-equity ratio
2018
2019
2020
2021
2022
2023
Amneal Pharmaceuticals Debt-to-Equity Ratio Growth & History (AMRX)
Amneal Pharmaceuticals's debt-to-equity ratio was 127.90 for fiscal 2023.
View full Amneal Pharmaceuticals company overviewAmneal Pharmaceuticals annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2023 | 2023-12-31 | 127.90 | 118.70 | +1290.29% |
| 2022 | 2022-12-31 | 9.20 | 1.32 | +16.81% |
| 2021 | 2021-12-31 | 7.88 | −1.71 | −17.85% |
| 2020 | 2020-12-31 | 9.59 | −2.07 | −17.73% |
| 2019 | 2019-12-31 | 11.65 | 6.13 | +110.91% |
| 2018 | 2018-12-31 | 5.52 | — | — |
Amneal Pharmaceuticals quarterly debt-to-equity ratio
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q2.26
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 77.83 | — | — |
| Q4 2023 | 2023-12-31 | 127.90 | 118.70 | +1290.29% |
| Q3 2023 | 2023-09-30 | 7.77 | −1.09 | −12.30% |
| Q2 2023 | 2023-06-30 | 8.11 | −1.35 | −14.31% |
| Q1 2023 | 2023-03-31 | 8.80 | 1.89 | +27.37% |
| Q4 2022 | 2022-12-31 | 9.20 | 1.32 | +16.81% |
| Q3 2022 | 2022-09-30 | 8.87 | 1.11 | +14.32% |
| Q2 2022 | 2022-06-30 | 9.46 | 1.51 | +19.06% |
| Q1 2022 | 2022-03-31 | 6.91 | −1.63 | −19.06% |
| Q4 2021 | 2021-12-31 | 7.88 | −1.71 | −17.85% |
| Q3 2021 | 2021-09-30 | 7.75 | −1.50 | −16.23% |
| Q2 2021 | 2021-06-30 | 7.95 | −1.18 | −12.97% |
| Q1 2021 | 2021-03-31 | 8.54 | −0.26 | −2.97% |
| Q4 2020 | 2020-12-31 | 9.59 | −2.07 | −17.73% |
| Q3 2020 | 2020-09-30 | 9.26 | −3.17 | −25.54% |
| Q2 2020 | 2020-06-30 | 9.13 | 3.22 | +54.35% |
| Q1 2020 | 2020-03-31 | 8.80 | 3.02 | +52.29% |
| Q4 2019 | 2019-12-31 | 11.65 | 6.13 | +110.91% |
| Q3 2019 | 2019-09-30 | 12.43 | 6.85 | +122.75% |
| Q2 2019 | 2019-06-30 | 5.92 | 0.50 | +9.13% |
| Q1 2019 | 2019-03-31 | 5.78 | — | — |
| Q4 2018 | 2018-12-31 | 5.52 | — | — |
| Q3 2018 | 2018-09-30 | 5.58 | — | — |
| Q2 2018 | 2018-06-30 | 5.42 | — | — |
Amneal Pharmaceuticals debt-to-equity ratio trends
Over the last five fiscal years, Amneal Pharmaceuticals's debt-to-equity ratio increased from 5.52 to 127.90, a change of 122.38. The latest reported quarter, Q2 2026, shows 77.83.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Amneal Pharmaceuticals source filings ↗